SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Strand Sven Erik) "

Sökning: WFRF:(Strand Sven Erik)

Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Ahlstedt, Jonas, et al. (författare)
  • Biodistribution and pharmacokinetics of recombinant α1-microglobulin and its potential use in radioprotection of kidneys.
  • 2015
  • Ingår i: American journal of nuclear medicine and molecular imaging. - e-Century Publishing Corporation. - 2160-8407. ; 5:4, s. 333-347
  • Tidskriftsartikel (refereegranskat)abstract
    • Peptide-receptor radionuclide therapy (PRRT) is a systemically administrated molecular targeted radiation therapy for treatment of neuroendocrine tumors. Fifteen years of clinical use show that renal toxicity, due to glomerular filtration of the peptides followed by local generation of highly reactive free radicals, is the main side-effect that limits the maximum activity that can be administrated for efficient therapy. α1-microglobulin (A1M) is an endogenous radical scavenger shown to prevent radiation-induced in vitro cell damage and protect non-irradiated surrounding cells. An important feature of A1M is that, following distribution to the blood, it is equilibrated to the extravascular compartments and filtrated in the kidneys. Aiming at developing renal protection against toxic side-effects of PRRT, we have characterized the pharmacokinetics and biodistribution of intravenously (i.v.) injected (125)I- and non-labelled recombinant human A1M and the (111)In- and fluorescence-labelled somatostatin analogue octreotide. Both molecules were predominantly localized to the kidneys, displaying a prevailing distribution in the cortex. A maximum of 76% of the injected A1M and 46% of the injected octreotide were present per gram kidney tissue at 10 to 20 minutes, respectively, after i.v. injection. Immunohistochemistry and fluorescence microscopy revealed a dominating co-existence of the two substances in proximal tubules, with a cellular co-localization in the epithelial cells. Importantly, analysis of kidney extracts displayed an intact, full-length A1M at least up to 60 minutes post-injection (p.i.). In summary, the results show a highly similar pharmacokinetics and biodistribution of A1M and octreotide, thus enabling the use of A1M to protect the kidneys tissue during PRRT.
2.
  • Altai, Mohamed, et al. (författare)
  • 188Re-ZHER2:V2, a Promising Affibody-Based Targeting Agent Against HER2-Expressing Tumors: Preclinical Assessment.
  • 2014
  • Ingår i: Journal of Nuclear Medicine. - Society of Nuclear Medicine. - 0161-5505. ; 55:11, s. 1842-1848
  • Tidskriftsartikel (refereegranskat)abstract
    • Affibody molecules are small (7 kDa) nonimmunoglobulin scaffold proteins with favorable tumor-targeting properties. Studies concerning the influence of chelators on biodistribution of (99m)Tc-labeled Affibody molecules demonstrated that the variant with a C-terminal glycyl-glycyl-glycyl-cysteine peptide-based chelator (designated ZHER2:V2) has the best biodistribution profile in vivo and the lowest renal retention of radioactivity. The aim of this study was to evaluate (188)Re-ZHER2:V2 as a potential candidate for radionuclide therapy of human epidermal growth factor receptor type 2 (HER2)-expressing tumors.
  •  
3.
  • Altai, Mohamed, et al. (författare)
  • Re-188-Z(HER2:V2), a Promising Affibody-Based Targeting Agent Against HER2-Expressing Tumors : Preclinical Assessment
  • 2014
  • Ingår i: Journal of Nuclear Medicine. - 0161-5505 .- 1535-5667. ; 55:11, s. 1842-1848
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Affibody molecules are small (7 kDa) nonimmunoglobulin scaffold proteins with favorable tumor-targeting properties. Studies concerning the influence of chelators on biodistribution of Tc-99m-labeled Affibody molecules demonstrated that the variant with a C-terminal glycyl-glycyl-glycyl-cysteine peptide-based chelator (designated Z(HER2:V2)) has the best biodistribution profile in vivo and the lowest renal retention of radioactivity. The aim of this study was to evaluate Re-188-Z(HER2:v2) as a potential candidate for radionuclide therapy of human epidermal growth factor receptor type 2 (HER2)-expressing tumors. Methods: Z(HER2:V2) was labeled with Re-188 using a gluconate-containing kit. Targeting of HER2-overexpressing SKOV-3 ovarian carcinoma xenografts in nude mice was studied for a dosimetry assessment. Results: Binding of Re-188-Z(HER2:V2) to living SKOV-3 cells was demonstrated to be specific, with an affinity of 6.4 +/- 0.4 pM. The biodistribution study showed a rapid blood clearance (1.4 +/- 0.1 percentage injected activity per gram [%ID/g] at 1 h after injection). The tumor uptake was 14 +/- 2, 12 +/- 2, 5 +/- 2, and 1.8 +/- 0.5 %IA/g at 1, 4, 24, and 48 h after injection, respectively. The in vivo targeting of HER2-expressing xenografts was specific. Already at 4 h after injection, tumor uptake exceeded kidney uptake (2.1 +/- 0.2 %IA/g). Scintillation-camera imaging showed that tumor xenografts were the only sites with prominent accumulation of radioactivity at 4 h after injection. Based on the biokinetics, a dosimetry evaluation for humans suggests that Re-188-Z(HER2:v2) would provide an absorbed dose to tumor of 79 Gy without exceeding absorbed doses of 23 Gy to kidneys and 2 Gy to bone marrow. This indicates that future human radiotherapy studies may be feasible. Conclusion: (188)ReZ(HER2:v2) can deliver high absorbed doses to tumors without exceeding kidney and bone marrow toxicity limits.</p>
  •  
4.
  • Altai, Mohamed, et al. (författare)
  • <sup>188</sup>Re-Z<sub>HER2:V2</sub>, a promising affibody-based targeting agent against HER2-expressing tumors preclinical assessment
  • 2014
  • Ingår i: Journal of Nuclear Medicine. - 0161-5505 .- 1535-5667. ; 55:11, s. 1842-1848
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Affibody molecules are small (7 kDa) nonimmunoglobulin scaffold proteins with favorable tumor-targeting properties. Studies concerning the influence of chelators on biodistribution of <sup>99m</sup>Tc-labeled Affibody molecules demonstrated that the variant with a C-terminal glycyl-glycyl-glycyl-cysteine peptide–based chelator (designated Z<sub>HER2:V2</sub>) has the best biodistribution profile in vivo and the lowest renal retention of radioactivity. The aim of this study was to evaluate <sup>188</sup>Re-Z<sub>HER2:V2</sub> as a potential candidate for radionuclide therapy of human epidermal growth factor receptor type 2 (HER2)–expressing tumors.</p><p><strong>Methods:</strong></p><p>Z<sub>HER2:V2</sub> was labeled with <sup>188</sup>Re using a gluconate-containing kit. Targeting of HER2-overexpressing SKOV-3 ovarian carcinoma xenografts in nude mice was studied for a dosimetry assessment.</p><p><strong>Results:</strong></p><p>Binding of <sup>188</sup>Re-Z<sub>HER2:V2</sub> to living SKOV-3 cells was demonstrated to be specific, with an affinity of 6.4 ± 0.4 pM. The biodistribution study showed a rapid blood clearance (1.4 ± 0.1 percentage injected activity per gram [%ID/g] at 1 h after injection). The tumor uptake was 14 ± 2, 12 ± 2, 5 ± 2, and 1.8 ± 0.5 %IA/g at 1, 4, 24, and 48 h after injection, respectively. The in vivo targeting of HER2-expressing xenografts was specific. Already at 4 h after injection, tumor uptake exceeded kidney uptake (2.1 ± 0.2 %IA/g). Scintillation-camera imaging showed that tumor xenografts were the only sites with prominent accumulation of radioactivity at 4 h after injection. Based on the biokinetics, a dosimetry evaluation for humans suggests that <sup>188</sup>Re-Z<sub>HER2:V2</sub> would provide an absorbed dose to tumor of 79 Gy without exceeding absorbed doses of 23 Gy to kidneys and 2 Gy to bone marrow. This indicates that future human radiotherapy studies may be feasible.</p><p><strong>Conclusion:</strong></p><p><sup>188</sup>Re-Z<sub>HER2:V2</sub> can deliver high absorbed doses to tumors without exceeding kidney and bone marrow toxicity limits.</p>
  •  
5.
  • Timmermand, OV, et al. (författare)
  • Preclinical efficacy of hK2 targeted [177Lu]hu11B6 for prostate cancer theranostics
  • 2019
  • Ingår i: Theranostics. - Ivyspring International Publisher. - 1838-7640. ; 9:8, s. 2129-2142
  • Tidskriftsartikel (refereegranskat)abstract
    • Androgen ablating drugs increase life expectancy in men with metastatic prostate cancer, but resistance inevitably develops. In a majority of these recurrent tumors, the androgen axis is reactivated in the form of increased androgen receptor (AR) expression. Targeting proteins that are expressed as a down-stream effect of AR activity is a promising rationale for management of this disease. The humanized IgG1 antibody hu11B6 internalizes into prostate and prostate cancer (PCa) cells by binding to the catalytic cleft of human kallikrein 2 (hK2), a prostate specific enzyme governed by the AR-pathway. In a previous study, hu11B6 conjugated with Actinium-225 (225Ac), a high linear energy transfer (LET) radionuclide, was shown to generate an AR-upregulation driven feed-forward mechanism that is believed to enhance therapeutic efficacy. We assessed the efficacy of hu11B6 labeled with a low LET beta-emitter, Lutetium-177 (177Lu) and investigated whether similar tumor killing and AR-enhancement is produced. Moreover, single-photon emission computed tomography (SPECT) imaging of 177Lu is quantitatively accurate and can be used to perform treatment planning. [177Lu]hu11B6 therefore has significant potential as a theranostic agent. Materials and Methods: Subcutaneous PCa xenografts (LNCaP s.c.) were grown in male mice. Biokinetics at 4-336 h post injection and uptake as a function of the amount of hu11B6 injected at 72 h were studied. Over a 30 to 120-day treatment period the therapeutic efficacy of different activities of [177Lu]hu11B6 were assessed by volumetric tumor measurements, blood cell counts, molecular analysis of the tumor as well as SPECT/CT imaging. Organ specific mean absorbed doses were calculated, using a MIRD-scheme, based on biokinetic data and rodent specific S-factors from a modified MOBY phantom. Tumor tissues of treated xenografts were immunohistochemically (IHC) stained for Ki-67 (proliferation) and AR, SA-β-gal activity (senescence) and analyzed by digital autoradiography (DAR). Results: Organ-to-blood and tumor-to-blood ratios were independent of hu11B6 specific activity except for the highest amount of antibody (150 µg). Tumor accumulation of [177Lu]hu11B6 peaked at 168 h with a specific uptake of 29 ± 9.1 percent injected activity per gram (%IA/g) and low accumulation in normal organs except in the submandibular gland (15 ± 4.5 %IA/g), attributed to a cross-reaction with mice kallikreins in this organ, was seen. However, SPECT imaging with therapeutic amounts of [177Lu]hu11B6 revealed no peak in tumor accumulation at 7 d, probably due to cellular retention of 177Lu and decreasing tumor volumes. For [177Lu]hu11B6 treated mice, tumor decrements of up to 4/5 of the initial tumor volume and reversible myelotoxicity with a nadir at 12 d were observed after a single injection. Tumor volume reduction correlated with injected activity and the absorbed dose. IHC revealed retained expression of AR throughout treatment and that Ki-67 staining reached a nadir at 9-14 d which coincided with high SA- β-gal activity (14 d). Quantification of nuclei staining showed that Ki-67 expression correlated negatively with activity uptake. AR expression levels in cells surviving therapy compared to previous timepoints and to controls at 30 d were significantly increased (p = 0.017). Conclusions: This study shows that hu11B6 labeled with the low LET beta-emitting radionuclide 177Lu can deliver therapeutic absorbed doses to prostate cancer xenografts with transient hematological side-effects. The tumor response correlated with the absorbed dose both on a macro and a small scale dosimetric level. Analysis of AR staining showed that AR protein levels increased late in the study suggesting a therapeutic mechanism, a feed forward mechanism coupled to AR driven response to DNA damage or clonal lineage selection, similar to that reported in high LET alpha-particle therapy using 225Ac labeled hu11B6, however emerging at a later timepoint.
6.
  • Elgqvist, Jörgen, et al. (författare)
  • Radiosensitivity of Prostate Cancer Cell Lines for Irradiation from Beta Particle-emitting Radionuclide ¹⁷⁷Lu Compared to Alpha Particles and Gamma Rays
  • 2016
  • Ingår i: Anticancer research. - International Institute of Cancer Research. - 1791-7530. ; 36:1, s. 103-109
  • Tidskriftsartikel (refereegranskat)abstract
    • AIM: The purpose of the present study was to investigate the radiosensitivity of the prostate cancer cell lines LNCaP, DU145, and PC3 when irradiated with beta particles emitted from (177)Lu, and to compare the effect with irradiation using alpha particles or gamma rays.MATERIALS AND METHODS: Cells were irradiated with beta particles emitted from (177)Lu, alpha particles from (241)Am, or gamma rays from (137)Cs. A non-specific polyclonal antibody was labeled with (177)Lu and used to irradiate cells in suspension with beta particles. A previously described in-house developed alpha-particle irradiator based on a (241)Am source was used to irradiate cells with alpha particles. External gamma-ray irradiation was achieved using a standard (137)Cs irradiator. Cells were irradiated to absorbed doses equal to 0, 0.5, 1, 2, 4, 6, 8, or 10 Gy. The absorbed doses were calculated as mean absorbed doses. For evaluation of cell survival, the tetrazolium-based WST-1 assay was used. After irradiation, WST-1 was added to the cell solutions, incubated, and then measured for level of absorbance at 450 nm, indicating the live and viable cells.RESULTS: LNCaP, DU145, and PC3 cell lines all had similar patterns of survival for the different radiation types. No significant difference in surviving fractions were observed between cells treated with beta-particle and gamma-ray irradiation, represented for example by the surviving fraction values (mean±SD) at 2, 6, and 10 Gy (SF2, SF6, and SF10) for DU145 after beta-particle irradiation: 0.700±0.090, 0.186±0.050 and 0.056±0.010, respectively. A strong radiosensitivity to alpha particles was observed, with SF2 values of 0.048±0.008, 0.018±0.006 and 0.015±0.005 for LNCaP, DU145, and PC3, respectively.CONCLUSION: The surviving fractions after irradiation using beta particles or gamma rays did not differ significantly at the absorbed dose levels and dose rates used. Irradiation using alpha particles led to a high level of cell killing. The results show that the beta-particle emitter (177)Lu as well as alpha-particles are both good candidates for radionuclide-therapy applications in the treatment of prostate cancer.
  •  
7.
  • Evans Axelsson, Susan, et al. (författare)
  • Preclinical evaluation of (111)In-DTPA-INCA-X anti-Ku70/Ku80 monoclonal antibody in prostate cancer.
  • 2014
  • Ingår i: American journal of nuclear medicine and molecular imaging. - e-Century Publishing Corporation. - 2160-8407. ; 4:4, s. 311-323
  • Tidskriftsartikel (refereegranskat)abstract
    • The aim of this investigation was to assess the Ku70/Ku80 complex as a potential target for antibody imaging of prostate cancer. We evaluated the in vivo and ex vivo tumor targeting and biodistribution of the (111)In-labeled human internalizing antibody, INCA-X ((111)In-DTPA-INCA-X antibody), in NMRI-nude mice bearing human PC-3, PC-3M-Lu2 or DU145 xenografts. DTPA-conjugated, non-labeled antibody was pre-administered at different time-points followed by a single intravenous injection of (111)In-DTPA-INCA-X. At 48, 72 and 96 h post-injection, tissues were harvested, and the antibody distribution was determined by measuring radioactivity. Preclinical SPECT/CT imaging of mice with and without the predose was performed at 48 hours post-injection of labeled DTPA-INCA-X. Biodistribution of the labeled antibody showed enriched activity in tumor, spleen and liver. Animals pre-administered with DTPA-INCA-X showed increased tumor uptake and blood content of (111)In-DTPA-INCA-X with reduced splenic and liver uptake. The in vitro and in vivo data presented show that the (111)In-labeled INCA-X antibody is internalized into prostate cancer cells and by pre-administering non-labeled DTPA-INCA-X, we were able to significantly reduce the off target binding and increase the (111)In-DTPA-INCA-X mAb uptake in PC-3, PC-3M-Lu2 and DU145 xenografts. The results are encouraging and identifying the Ku70/Ku80 antigen as a target is worth further investigation for functional imaging of prostate cancer.
8.
  • Evans-Axelsson, Susan, et al. (författare)
  • Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone
  • 2012
  • Ingår i: Cancer Biotherapy and Radiopharmaceuticals. - 1084-9785 .- 1557-8852. ; 27:4, s. 243-251
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>This study investigated the feasibility of targeting the free, unbound forms of prostate-specific antigen (fPSA) for <em>in vivo</em> imaging of prostate adenocarcinomas (PCa), as PSA is produced and secreted at abundance during every clinical stage and grade of PCa, including castration-resistant disease. We injected <sup>125</sup>I-labeled monoclonal antibody PSA30 (specific for an epitope uniquely accessible on fPSA alone) intravenously in male nude mice carrying subcutaneous xenografts of LNCaP tumors (<em>n</em>=36). Mice were sacrificed over a time course from 4 hours to 13 days after injecting <sup>125</sup>I-labeled PSA30. Tissue uptake of <sup>125</sup>I-PSA30 at 48 and 168 hours after intravenous injection was compared with two clinically used positron emission tomography radiopharmaceuticals, <sup>18</sup>F-fluoro-deoxy-glucose (<sup>18</sup>F-FDG) or <sup>18</sup>F-choline, in cryosections using Digital AutoRadiography (DAR) and also compared with immunohistochemical staining of PSA and histopathology. On DAR, the areas with high <sup>125</sup>I-PSA30 uptake corresponded mainly to morphologically intact and PSA-producing LNCaP cells, but did not associate with the areas of high uptake of either <sup>18</sup>F-FDG or <sup>18</sup>F-choline. Biodistribution of <sup>125</sup>I-PSA30 measured in dissected organs <em>ex vivo</em> during 4 to 312 hours after intravenous injection demonstrated maximum selective tumor uptake 24–48 hours after antibody injection. Our data showed selective uptake <em>in vivo</em> of a monoclonal antibody highly specific for fPSA in LNCaP cells. Hence, <em>in vivo</em> imaging of fPSA may be feasible with putative usefulness in disseminated PCa.</p> <p></p>
  •  
9.
  • Evans Axelsson, Susan, et al. (författare)
  • Targeting Free Prostate-Specific Antigen for In Vivo Imaging of Prostate Cancer Using a Monoclonal Antibody Specific for Unique Epitopes Accessible on Free Prostate-Specific Antigen Alone.
  • 2012
  • Ingår i: Cancer Biotherapy & Radiopharmaceuticals. - Mary Ann Liebert, Inc.. - 1557-8852. ; 27:4, s. 243-251
  • Tidskriftsartikel (refereegranskat)abstract
    • This study investigated the feasibility of targeting the free, unbound forms of prostate-specific antigen (fPSA) for in vivo imaging of prostate adenocarcinomas (PCa), as PSA is produced and secreted at abundance during every clinical stage and grade of PCa, including castration-resistant disease. We injected (125)I-labeled monoclonal antibody PSA30 (specific for an epitope uniquely accessible on fPSA alone) intravenously in male nude mice carrying subcutaneous xenografts of LNCaP tumors (n=36). Mice were sacrificed over a time course from 4 hours to 13 days after injecting (125)I-labeled PSA30. Tissue uptake of (125)I-PSA30 at 48 and 168 hours after intravenous injection was compared with two clinically used positron emission tomography radiopharmaceuticals, (18)F-fluoro-deoxy-glucose ((18)F-FDG) or (18)F-choline, in cryosections using Digital AutoRadiography (DAR) and also compared with immunohistochemical staining of PSA and histopathology. On DAR, the areas with high (125)I-PSA30 uptake corresponded mainly to morphologically intact and PSA-producing LNCaP cells, but did not associate with the areas of high uptake of either (18)F-FDG or (18)F-choline. Biodistribution of (125)I-PSA30 measured in dissected organs ex vivo during 4 to 312 hours after intravenous injection demonstrated maximum selective tumor uptake 24-48 hours after antibody injection. Our data showed selective uptake in vivo of a monoclonal antibody highly specific for fPSA in LNCaP cells. Hence, in vivo imaging of fPSA may be feasible with putative usefulness in disseminated PCa.
10.
  • Evertsson, Maria, et al. (författare)
  • Combined Magnetomotive ultrasound, PET/CT, and MR imaging of (68)Ga-labelled superparamagnetic iron oxide nanoparticles in rat sentinel lymph nodes in vivo
  • 2017
  • Ingår i: Scientific Reports. - Nature Publishing Group. - 2045-2322. ; 7:1
  • Tidskriftsartikel (refereegranskat)abstract
    • Current methods for intra-surgical guidance to localize metastases at cancer surgery are based on radioactive tracers that cause logistical challenges. We propose the use of a novel ultrasound-based method, magnetomotive ultrasound (MMUS) imaging that employ a nanoparticle-based contrast agent that also may be used for pre-operative PET/MRI imaging. Since MMUS is radiation free, this eliminates the dependence between pre- and intra-operative imaging and the radiation exposure for the surgical staff. This study investigates a hypothetical clinical scenario of pre-operative PET imaging, combined with intra-operative MMUS imaging, implemented in a sentinel lymph node (SLN) rat model. At one-hour post injection of (68)Ga-labelled magnetic nanoparticles, six animals were imaged with combined PET/CT. After two or four days, the same animals were imaged with MMUS. In addition, ex-vivo MRI was used to evaluate the amount of nanoparticles in each single SLN. All SLNs were detectable by PET. Four out of six SLNs could be detected with MMUS, and for these MMUS and MRI measurements were in close agreement. The MRI measurements revealed that the two SLNs undetectable with MMUS contained the lowest nanoparticle concentrations. This study shows that MMUS can complement standard pre-operative imaging by providing bedside real-time images with high spatial resolution.
Skapa referenser, mejla, bekava och länka
Åtkomst
fritt online (39)
Typ av publikation
tidskriftsartikel (140)
konferensbidrag (11)
bokkapitel (8)
forskningsöversikt (5)
samlingsverk (redaktörskap) (1)
bok (1)
visa fler...
doktorsavhandling (1)
visa färre...
Typ av innehåll
refereegranskat (161)
övrigt vetenskapligt (20)
Författare/redaktör
Strand, Sven-Erik, (166)
Ljungberg, Michael, (53)
Tennvall, Jan, (42)
Jönsson, Bo-Anders, (27)
Ohlsson, Tomas G, (23)
Wingårdh, Karin, (19)
visa fler...
Sjögreen Gleisner, K ... (17)
Garkavij, Michael, (16)
Lindén, Ola, (15)
Sjögren, Hans Olov, (14)
Larsson, Erik, (13)
Ulmert, David, (10)
Tran, TA, (10)
Tran, Thuy, (10)
Strand, SE (10)
Hindorf, Cecilia, (10)
Evans Axelsson, Susa ... (10)
Norrgren, Kristina, (9)
Mårtensson, Linda, (9)
Lilja, Hans, (8)
Bjartell, Anders, (7)
Erlandsson, Kjell (7)
Sandell, Anders, (6)
Salford, Leif, (6)
Thörne, Johan (6)
Grafström, Gustav, (6)
Ljunggren, Kaj, (6)
Thorek, Daniel L J, (5)
Ceberg, Crister, (5)
Tolmachev, Vladimir, (5)
Strand, Joanna (5)
Larson, Steven M., (5)
Fredriksson, Sarah, (5)
Ingvar, Christian, (5)
Cavallin-Ståhl, Eva, (5)
Norgren, Lars, (4)
Sjöberg, Trygve, (4)
Holmqvist, Bo, (4)
Ståhlberg, Freddy, (4)
Knutsson, Linda, (4)
Sandström, Mattias, (4)
Ahlstedt, Jonas, (4)
Åkerström, Bo, (4)
Jansson, Tomas, (4)
Kjellman, Pontus, (4)
Axelsson, Johan, (4)
Lindgren, Lars, (4)
Wennerberg, Johan, (4)
Arvidsson, Dag, (4)
Qvarfordt, Peter (4)
visa färre...
Lärosäte
Lunds universitet (161)
Karolinska Institutet (10)
Uppsala universitet (4)
Göteborgs universitet (3)
Kungliga Tekniska Högskolan (1)
swepub_uni:mau_t (1)
Språk
Engelska (166)
Svenska (1)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (158)
Naturvetenskap (6)
Teknik (2)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy